Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:AEZSNASDAQ:ALZNNASDAQ:BCLI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03$0.04$0.00▼$0.78$1.49M1.187,440 shs30 shsAEZSAeterna Zentaris$3.41+2.1%$3.16$3.96▼$12.00$6.12M1.557,305 shs696 shsALZNAlzamend Neuro$5.44+63.9%$6.19$3.06▼$135.54$4.36M-0.16404,588 shs77.68 million shsBCLIBrainstorm Cell Therapeutics$1.12+5.7%$1.11$0.72▼$8.25$8.89M0.35350,227 shs426,691 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-6.93%+4.80%+16.33%-86.83%AEZSAeterna Zentaris+2.12%-3.92%+8.80%+17.61%-66.72%ALZNAlzamend Neuro+63.86%+52.81%-9.05%-26.29%-89.54%BCLIBrainstorm Cell Therapeutics+5.66%+0.90%+3.23%-30.00%-85.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AALZNAlzamend Neuro3.3147 of 5 stars3.54.00.00.03.04.20.0BCLIBrainstorm Cell Therapeutics4.274 of 5 stars3.55.00.04.72.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AAEZSAeterna Zentaris 0.00N/AN/AN/AALZNAlzamend Neuro 3.00Buy$180.003,208.82% UpsideBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,578.57% UpsideCurrent Analyst Ratings BreakdownLatest ADXS, ALZN, AEZS, and BCLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$288.00 ➝ $180.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.46N/AN/A($2.06) per share-0.02AEZSAeterna Zentaris$2.37M2.58N/AN/A$14.99 per share0.23ALZNAlzamend NeuroN/AN/AN/AN/A($3.52) per shareN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)ALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/AN/A-289.14%7/29/2025 (Estimated)BCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)Latest ADXS, ALZN, AEZS, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A3/10/2025Q3 2025ALZNAlzamend Neuro-$2.61-$1.71+$0.90-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AAEZSAeterna ZentarisN/AN/AN/AN/AN/AALZNAlzamend NeuroN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AAEZSAeterna ZentarisN/A5.945.93ALZNAlzamend NeuroN/A3.803.80BCLIBrainstorm Cell TherapeuticsN/A0.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%AEZSAeterna Zentaris0.73%ALZNAlzamend Neuro49.61%BCLIBrainstorm Cell Therapeutics14.33%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%AEZSAeterna Zentaris0.10%ALZNAlzamend Neuro30.21%BCLIBrainstorm Cell Therapeutics6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataALZNAlzamend Neuro4801,0004.86 millionNo DataBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableADXS, ALZN, AEZS, and BCLI HeadlinesRecent News About These CompaniesEquities Analysts Offer Predictions for BCLI Q2 EarningsMay 30 at 2:07 AM | americanbankingnews.comBCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial…May 27 at 6:22 PM | finance.yahoo.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27 at 7:00 AM | prnewswire.comStockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)May 22, 2025 | americanbankingnews.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comBrainStorm Cell Therapeutics Inc.: BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALSMay 19, 2025 | finanznachrichten.deMicro Cap Bid Up Aggressively On FDA Clearance AnnouncementMay 19, 2025 | msn.comBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALSMay 19, 2025 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | tmcnet.comBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | prnewswire.comBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19May 15, 2025 | prnewswire.comBrainStorm Cell Therapeutics Q1 2025 Earnings PreviewMay 14, 2025 | msn.comBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025May 7, 2025 | prnewswire.comBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development SummitMay 6, 2025 | prnewswire.comBrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 MeetingApril 29, 2025 | prnewswire.comBrainstorm Cell Therapeutics adjusts quorum requirementApril 23, 2025 | investing.comBrainstorm seeking FDA’s OK to launch NurOwn Phase 3b trialApril 17, 2025 | alsnewstoday.comBrainStorm submits IND amendment to FDA for Phase 3b trial of NurOwn in ALSApril 10, 2025 | markets.businessinsider.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALSApril 10, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXS, ALZN, AEZS, and BCLI Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 0.00 (0.00%) As of 05/28/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Aeterna Zentaris NASDAQ:AEZS$3.41 +0.07 (+2.12%) As of 05/28/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Alzamend Neuro NASDAQ:ALZN$5.44 +2.12 (+63.86%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$5.57 +0.13 (+2.39%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Brainstorm Cell Therapeutics NASDAQ:BCLI$1.12 +0.06 (+5.66%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.09 -0.03 (-2.68%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
